Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment.
The aim of this study was to identify recurrent respiratory papillomatosis patients who may benefit from interferon (IFN)-alpha treatment and to determine the means of IFN-alpha action. The presence of human papillomavirus (HPV) and viral load and proliferation rate in pre-, ongoing and post-treatment respiratory papillomatosis biopsies were examined retrospectively in 25 patients, 18 of whom were IFN-alpha treated and seven of whom were IFN-alpha non-treated. Using PCR, HPV was found to be present in 20/25 respiratory papillomatosis patients and HPV type was determined for 18/25 patients (12 HPV6 and six HPV11). Eighteen of the patients were treated with IFN-alpha, 14 of whom were HPV positive (eight HPV6, five HPV11 and one undefined HPV). Response to IFN-alpha therapy was observed in 12 patients (7/8 HPV6, 3/5 HPV11, 1/1 undefined HPV and 1/4 HPV negative), while six patients (1/8 HPV6, 2/5 HPV11 and 3/4 HPV negative) did not respond to therapy. Viral load, determined by quantitative real-time PCR (between 0.03 and 533 HPV copies per cell), and proliferation rate, determined as the percentage of Ki-67-positive cells (between 8 and 54 %), were similar in IFN-alpha-treated and non-treated patients and were generally unaffected by IFN-alpha treatment. In summary, most (12/18) IFN-alpha-treated patients responded to therapy. Moreover, there was a tendency for patients with HPV6-positive (7/8) respiratory papillomatosis to respond more frequently to IFN-alpha therapy than patients with HPV11 (3/5) or HPV-negative (1/4) respiratory papillomatosis. Finally, the presence of HPV and viral load and proliferation in respiratory papillomatosis biopsies was similar in patients treated or not with IFN-alpha and were in general unaffected by IFN-alpha treatment.
Szeps
Michael
M
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Dahlgren
Liselotte
L
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Aaltonen
Leena-Maija
LM
Department of Oto-Rhino-Laryngology, Helsinki University Hospital, Helsinki, Finland.
Öhd
John
J
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Kanter-Lewenshon
Lena
L
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Dahlstrand
Hanna
H
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Munck-Wikland
Eva
E
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Grandér
Dan
D
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Dalianis
Tina
T
Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005387:Finland; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000821:virology; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000821:virology; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy* / Q000821:virology; D012189:Retrospective Studies; D013548:Sweden; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D016898:Interferon-alpha